IP Verse

Crystalline Forms Of An Androgen Receptor Modulator

Patent No. EP3533792 (titled "Crystalline Forms Of An Androgen Receptor Modulator") was filed by Aragon Pharmaceuticals on Jun 4, 2013. The application was issued on May 5, 2021.

Patent Summary

Crystalline forms of the androgen receptor modulator 4-[7-(6-cyano-5-trifluoromethylpyridin-3-yl)-8-oxo-6-thioxo-5,7-diazaspiro[3.4]oct-5-yl]-2-fluoro-N-methylbenzamide, including Form B, and pharmaceutical compositions thereof for treating diseases associated with androgen receptor activity, such as prostate cancer.

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
GENERICS UKFeb 4, 2022TER MEER STEINMEISTER & PARTNER

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3533792

ARAGON PHARMACEUTICALS
Application Number
EP19169275A
Filing Date
Jun 4, 2013
Status
Opposition Rejected
Aug 2, 2024
Publication Date
May 5, 2021
External Links
Slate, Register , Google Patents